Q-omics provides the consensus-scored ZNF608 profile across patient tissues and cancer cell-line models. ZNF608 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF608 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF608 RNA expression shows 19,913 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, KICH, and KIRP as cancer lineages where ZNF608 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF608 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF608 survival associations across molecular data types. ZNF608 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF608 RNA expression–survival associations across cancer types. High ZNF608 expression shows unfavorable associations in CESC, OV, KIRP, ACC and STAD, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF608 RNA expression.
This table summarizes ZNF608 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF608. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF608 shows lower tumor expression in KICH, LUSC, HNSC and BRCA and higher tumor expression in KIRC and KIRP. The KICH box plot shows higher ZNF608 RNA expression in normal versus tumor tissue (log2 FC = −2.314, t-test p < 0.001).
This table shows molecular features associated with ZNF608 in patient tissues and cancer cell lines. In patient samples, ZNF608 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF608 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
